SNCE SCIENCE 37 HLDGS INC

Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022

Science 37 to Report Third Quarter 2022 Financial Results on November 10, 2022

RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report third quarter 2022 financial results after the market closes on Thursday, November 10, 2022. Company management will host a corresponding conference call on Friday, November 11, 2022, at 8:30 a.m. Eastern Time.

The conference call can be accessed by registering online for dial-in information or via live audio webcast at: . Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.

A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit .

Contacts:

MEDIA INQUIRIES:

Drew Bustos

Science 37

Phone: (610) 417-6953

Email:

INVESTOR RELATIONS:

Steve Halper

Managing Director

LifeSci Advisors

Phone: (646) 876-6455

Email:



EN
01/11/2022

Underlying

SNCESCIENCE 37 HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCIENCE 37 HLDGS INC

 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Pha...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the successful completion of its second FDA inspection, reaffirming the quality of its Direct-to-Patient Site for clinical research. The inspection resulted in a No Action Indicated (NAI) categorization, with no objectionable conditions noted and no Form 483 issued. Led by Science 37's internal Quality Assurance & Compliance team, the inspection focused on the company’s role...

April 8, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation Seasoned Strategist and Former Chief Commercial Officer Poised to Accelerate Access and Equity in Clinical Research MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client ...

January 14, 2025 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, . The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that t...

November 21, 2024 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Aw...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials Top Honor Recognizes Science 37’s Visionary Innovation, Market-Leading Performance, and Unmatched Customer Care in the Decentralized Clinical Trials Industry MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, , a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched cu...

September 16, 2024 1 EN
 PRESS RELEASE
Free
SNCE SCIENCE 37 HLDG...

Science 37 Unveils New Corporate Headquarters in Research Triangle Par...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC 19,000-square-foot facility reflects the company’s recent growth and continued commitment to the region MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- , a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportun...

August 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch